Institutional members access full text with Ovid®

Share this article on:

A Rational Approach to the Management of Recurrent or Persistent Ovarian Carcinoma

THIGPEN, TATE MD

Clinical Obstetrics & Gynecology: March 2012 - Volume 55 - Issue 1 - p 114–130
doi: 10.1097/GRF.0b013e31824b9bc5
Ovarian Cancer

Evidence supports the current paradigm for the management of patients with recurrent or persistent ovarian carcinoma. The paradigm requires that patients be classified as platinum-sensitive or platinum-resistant. Patients who achieve a complete response with platinum-based therapy and experience at least 6 months free from recurrence should be categorized as having chemosensitive disease and should be retreated with carboplatin-based doublets. Patients who progress while receiving treatment, whose best response is stable disease, or who experience a complete response of <6 months duration should be categorized as having chemoresistant disease and should be treated with a nonplatinum single agent.

Division of Oncology, University of Mississippi Medical Center, Jackson, Mississippi

The author declares that he has nothing to disclose.

Correspondence: Tate Thigpen, MD, Division of Oncology, University of Mississippi Medical Center, Jackson, MS. E-mail: jtthigpen@att.net

© 2012 Lippincott Williams & Wilkins, Inc.